Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors during the central anxious system, conolidine modulates alternate molecular targets. A Science Innovations research uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CX